Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Infections and Mycoses Clear all
Terminated Phase 3 Interventional Results available

Hidradenitis Suppurativa Study of Izokibep

NCT05905783
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Placebo, Izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

NCT00000641
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
16
States / cities
Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

NCT05399641
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 23, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

NCT01208129
View directory record Official record
Conditions
Onychomycosis
Interventions
NAB001, Placebo control
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tucson, Arizona • Phoenix, Arkansas • Rogers, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)

NCT01169402
View directory record Official record
Conditions
Cardiopulmonary Arrest, Fungal Infection
Interventions
Fluconazole
Drug
Lead sponsor
Michael Cohen-Wolkowiez
Other
Eligibility
Up to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Jul 23, 2026, 10:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 23, 2026, 10:59 AM EDT
Completed No phase listed Observational

CTTI Risk Factors for HABP/VABP Study

NCT02689531
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
7,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients

NCT03168841
View directory record Official record
Conditions
Onychomycosis
Interventions
Efinaconazole Topical
Drug
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2008 · Synced Jul 23, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Results available

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

NCT01740388
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Besifloxacin, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
1 Year and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Not applicable Interventional

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

NCT00000796
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
21
States / cities
Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 23, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis

NCT00970749
View directory record Official record
Conditions
Chlamydia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jul 23, 2026, 10:59 AM EDT
Completed No phase listed Observational

Network on Antimicrobial Resistance in Staphylococcus Aureus

NCT00341913
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125
View directory record Official record
Conditions
Anthrax
Interventions
BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo)
Biological · Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002076
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Oakland, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:59 AM EDT
Recruiting Phase 2 Interventional

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
AZD5148, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Phoenix, Arizona • Chula Vista, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

NCT03313050
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap, polysaccharide
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jul 23, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Our Future Generation: Promotion of Protective Sexual Health Practices Among Native American Youth and Young Adults Through an Assets-based Self-care Intervention

NCT03895320
View directory record Official record
Conditions
Sexual Behavior, Unprotected Sex, Gonorrhea, Chlamydia, Trichomonas, Sexually Transmitted Diseases, Adolescent Behavior, Self Evaluation
Interventions
Sexual Health Risk Assessment, Sexual Health Score, Sexual Health Messaging, Water SSB Quiz, Water SSB Score, Water SSB Messaging, STI Screening
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
14 Years to 26 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pneumococcal Reference Standard

NCT00479323
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Pneumovax 23
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

NCT00001017
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

NCT04553068
View directory record Official record
Conditions
Sexually Transmitted Diseases, Gonorrhea, Chlamydia
Interventions
EVO100, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 23, 2026, 10:59 AM EDT
Recruiting No phase listed Observational

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT01904188
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions
Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
2
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 10:59 AM EDT
Completed Not applicable Interventional

An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy

NCT00002089
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Groton, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:59 AM EDT